Safety and efficacy of eculizumab for the prevention of antibody‐mediated rejection after deceased‐donor kidney transplantation in patients with preformed donor‐specific antibodies

The presence of preformed donor‐specific antibodies in transplant recipients increases the risk of acute antibody‐mediated rejection (AMR). Results of an open‐label single‐arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased‐donor kidney trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Glotz, Denis, Russ, Graeme, Rostaing, Lionel, Legendre, Christophe, Tufveson, Gunnar, Chadban, Steve, Grinyó, Josep, Mamode, Nizam, Rigotti, Paolo, Couzi, Lionel, Büchler, Matthias, Sandrini, Silvio, Dain, Bradley, Garfield, Mary, Ogawa, Masayo, Richard, Tristan, Marks, William H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328661/
https://www.ncbi.nlm.nih.gov/pubmed/31012541
http://dx.doi.org/10.1111/ajt.15397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328661/
https://www.ncbi.nlm.nih.gov/pubmed/31012541
http://dx.doi.org/10.1111/ajt.15397

Ejemplares similares